ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: At the turn of the century, the development of a modern small-molecule BCR-ABL tyrosine-kinase inhibitor (TKI) imatinib mesylate profoundly improved CML outcomes [9].